Overview of the use of recombinant factor VIIa in children
John Puetz Department of Pediatrics, Division of Hematology/Oncology, Cardinal Glennon Children's Medical Center, Saint Louis University, St Louis, MO, USA Abstract: Recombinant factor VIIa (rFVIIa) was initially developed as a bypassing agent to control bleeding in people with hemophilia...
Main Author: | Puetz J |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2014-10-01
|
Series: | Pediatric Health, Medicine and Therapeutics |
Online Access: | http://www.dovepress.com/overview-of-the-use-of-recombinant-factor-viia-in-children-peer-reviewed-article-PHMT |
Similar Items
-
Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients
by: John Puetz
Published: (2010-06-01) -
Use of recombinant factor VIIa for emergency reversal of anticoagulation
by: Ingerslev J, et al.
Published: (2007-01-01) -
Use of recombinant factor VIIa in orthotopic liver transplant
by: Pradeep Bhatia
Published: (2011-01-01) -
HEMOPHILIA INHIBITOR PATIENTS: THE USE OF RECOMBINANT FACTOR VIIa
by: Dušan Andoljšek, et al.
Published: (2004-12-01) -
Recombinant Factor VIIa : A Universal Haemostatic Agent?
by: Gill R, et al.
Published: (2006-01-01)